ALGORAE PHARMACEUTICALS LIMITED — Director's Dealing 2013

Dec 15, 2013

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Living Cell Technologies Limited
ABN	14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Andrea Louise Grant
Date of last notice	24 January 2013

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change	10 December 2013
No. of securities held prior to change	250,000 unlisted options exercisable at
	$0.10 each and expiring 23/12/2017
	250,000 unlisted options exercisable at
	$0.10 each and expiring 23/12/2018
Class	Unlisted Options
Number acquired	A) 100,000
	B) 100,000
Number disposed	Nil
Value/Consideration	A) $0.10 each
Note: If consideration is non-cash, provide details and estimatedvaluation	B) $0.15 each

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	No. of securities held after change	250,000 unlisted options exercisable at$0.10 each and expiring 23/12/2017250,000 unlisted options exercisable at$0.10 each and expiring 23/12/2018100,000 unlisted options exercisable at$0.10 each, vesting 06/03/2014 andexpiring 06/03/2018100,000 unlisted options exercisable at$0.15 each, vesting 06/03/2015 andexpiring 06/03/2018
		,$0.10 each, vesting 06/03/2014 andexpiring 06/03/2018100,000 unlisted options exercisable at
		$0.15 each, vesting 06/03/2015 andexpiring 06/03/2018
Nature of changeExample: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participation inbuy-back	Nature of changeExample: on-market trade, off-market trade, exercise of options,	IssueofOptionsapprovedbyhrhldr t th AGM hld n 1
	issue of securities under dividend reinvestment plan, participation inbuy-back	saeoes a e e oNovember 2013

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Detail of contract	N/A	N/A
Nature of interest
Name of registered holder(if issued securities)
	ame of registered holderf issued securities)
D	ate of change
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed	o. and class of securities to whichterest related prior to changeote: Details are only required for a contract in
Interest acquired
Interest disposed
Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation
Interest after change

Part 3 –[+] Closed period

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	No
If so, was prior written clearance provided to allow the tradeto proceed during this period?
If prior written clearance was provided, on what date was thisprovided?

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3